Ibiglustat

SKU: orb1226363

Description

An orally active, selective and potent Glucosylceramide synthase (GCS) inhibitor with central nervous system (CNS) access; exhibits significantly lower tissue levels of GL-3 and lyso-GL-3 and a delayed progression of a thermal nociceptive response in administered Fabry mice; shows favorable pharmacological properties and safety profile.Other Indication Phase 2 Clinical(In Vitro):Ibiglustat (SAR402671) (1 μM, 15 days; Fabry disease (FD) cells) is close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes.

Key Properties

• CAS Number: 1401090-53-6
• MW: 389.49
• Purity: >98% (HPLC)
• Formula: C₂₀H₂₄FN₃O₂S
• SMILES: O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C
• Target: glucosylceramide synthase
• Solubility: DMSO: 10 mM （ < 1 mg/ml refers to the product slightly soluble or insoluble )

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Venglustat | Genz-682452 | GZ452

Quick Database Links

Gene Symbol

glucosylceramide synthase